What is a subcutaneous anti-amyloid antibody, and why does it matter for access?

What it is

A subcutaneous anti-amyloid antibody is the same active drug as the IV-infused version, formulated and dosed for delivery as an injection just under the skin - typically in the abdomen or upper thigh - rather than into a vein over the course of a clinic visit. The drug molecule is the same. What changes is how it gets into the body.

For anti-amyloid antibodies in Alzheimer's disease, the IV-infused versions are the originally approved formulations: lecanemab as a biweekly infusion, donanemab as a four-weekly infusion. Both sponsors are also developing subcutaneous versions of the same drugs, with the explicit intent of moving the delivery from a specialised infusion centre to a much wider range of settings.

Why a different delivery route changes things

The current IV infusion model has a specific operational shape:

• The patient travels to an infusion centre.
• Vascular access is established and the drug is infused over an hour or so.
• The patient is observed for infusion-related reactions.
• The visit is repeated on the standing dose schedule, indefinitely.

A subcutaneous version replaces all of that with an injection that takes a few minutes, can be self-administered or family-administered after training, and can plausibly be done at home or in a primary care setting. The same patient who currently needs a biweekly trip to a specialised centre might, with the subcutaneous version, need a much less elaborate delivery touch.

The infusion-chair constraint has been one of the most-discussed rate limits on anti-amyloid rollout in practice - covered in our Signal on the lecanemab infusion bottleneck. A subcutaneous formulation directly addresses that constraint.

What it does not change

This is the part that often gets compressed in the access conversation, and is worth holding clearly.

The MRI surveillance requirement is unchanged. ARIA - amyloid-related imaging abnormalities - is a class effect of anti-amyloid therapy, not a delivery-route effect. The current FDA labels require serial brain MRI on a defined schedule to monitor for ARIA, and the surveillance schedule is built around the underlying biology of amyloid clearance. A subcutaneous formulation does not change that biology and does not change the surveillance requirement. MRI capacity, neurology workforce to interpret it, and the protocols for managing positive findings remain the same regardless of how the drug is administered.

The eligibility workup is unchanged. APOE genotyping, amyloid confirmation by PET or CSF, the cognitive assessment, and the biomarker triage that precedes the treatment decision are all the same regardless of whether the eventual formulation is IV or subcutaneous. A patient still needs to be screened, confirmed, and counselled before initiation.

The drug-drug interactions, contraindications, and adverse-event profile are essentially the same. The active molecule has not changed.

The cost and reimbursement framework will need to be re-established. A subcutaneous version will get its own labelling, its own coverage decisions, and its own pricing strategy. Whether commercial payers and CMS treat the subcutaneous version on parity with the IV version is a separate decision the systems make.

Why this matters for the rollout shape

Three things follow from a successful subcutaneous transition, in approximate order of certainty.

Site capacity expands. Removing the infusion-chair requirement opens delivery to a much wider range of settings. Primary care offices, rural clinics, home administration - all become operationally feasible in a way they currently are not. Our Insight on why the anti-amyloid rollout is rate-limited by infrastructure, not science covers the structural shape of this constraint and what relief from it implies.

The eligible patient pool that can actually receive treatment grows. A patient who lives far from an infusion centre, or who can't easily commit to a biweekly clinic visit, is currently unlikely to start treatment. A self-administered weekly injection meaningfully changes that calculus.

MRI capacity becomes proportionally more binding. The other major operational constraint - MRI surveillance for ARIA - is unchanged by the formulation. As the infusion bottleneck eases, MRI capacity becomes the larger remaining constraint. The system question will then be how to scale the surveillance side as fast as the delivery side scales.

Where it sits as of mid-2026

Subcutaneous lecanemab has been submitted to regulators and is under review. Subcutaneous donanemab is in later development. The exact timing and specific labelling will be set by the agency reviews and sponsor disclosures over the coming quarters. The current state is tracked in our Signal on subcutaneous anti-amyloid formulations and the broader treatment context is in our snapshot of disease-modifying therapies for 2026.

What this means for patients and families

If a patient is currently in treatment with the IV version: the subcutaneous version, once approved and adopted by their clinical team, would mean fewer infusion-centre visits and a much simpler logistical pattern around the treatment. The treatment itself - same molecule, same monitoring, same expected effect - would not change.

If a patient is not currently in treatment because of access constraints: the subcutaneous version may make access materially easier, particularly if the constraint was the infusion-centre side. It is unlikely to remove the constraint if the issue was on the eligibility, diagnostic confirmation, or MRI surveillance side.

This page is a plain-language primer. It is not medical advice. Decisions about treatment belong with the patient and their clinical team.